> Novogen has severed ties with CEO and Managing Director Christopher Naughton, who also was terminated as CEO of the company's oncology subsidiary Marshall Edwards. CFO David Seaton will take over as acting CEO until a permanent chief executive for Marshall Edwards is found-after which a permanent CEO will be appointed at Novogen.
> Girindus has named Marc Lemaître as CEO of its U.S. unit.
> Ontario-based Nuvo Research has announced that President and CEO Henrich Guntermann will concentrate on the development and commercialization of WF10, the company's autoimmune drug platform. Vice Chairman John London will assume the role of company president, as well as co-CEO with current Chairman Dan Chicoine. Bradley Galer, VP and GM of the company's pain group, will become president of that unit.
> BioXell has parted ways with Chief Medical Officer Laurence Skillern, who joined the company in February.
> Optos has tapped Christine Soden as chief financial officer and to the board of directors.
> The Vancouver, B.C.-based Centre for Drug Research and Development has appointed Karimah Es Sabar as senior vice president, business and strategic affairs.
> Nektar Therapeutics promotes Lorianne Masuoka to senior vice president and chief medical officer.
> Spain's CELLERIX has appointed José Luis Bravo as its VP global medical and regulatory.
> MAP Pharmaceuticals has announced the appointment of Alan Petro to the newly created position of VP, manufacturing and technical operations to prepare for the potential commercialization of Levadex orally inhaled migraine therapy.
> Emergent BioSolutions has tapped Steven Chatfield as SVP, biodefense. Chatfield rejoins the Emergent after serving as executive director of the U.K. Health Protection Agency and leading the agency's Centre for Emergency Preparedness and Response.
> Covagen announced the closing of a financing round with Ventech joining as a new investor. Karl Nägler of Ventech will join board of Covagen, which also added Christoph Lengauer, VP & global head of oncology, discovery research at Sanofi-Aventis, and Christoph Heusser former member of the biologic advisory board at Novartis, to its scientific advisory board.
> Karolinska Development AB and Pergamum AB announced today the appointment of Jørgen Thorball as chairman of the board of directors of Pergamum AB.
> Canaan Partners has appointed Tim Shannon as venture partner. In this capacity, he will support the firm's current healthcare portfolio companies and identify new investment opportunities.
> Cytochroma has named Peter Moldt to its board of directors. Moldt will replace Ulrik Spork as the Novo A/S representative on the company's board.
> Cannabis Science has reported that Drs. Ben Johnson, Allan Shackleford and William Courtney will become members of its recently formed scientific advisory board.